Future Biosimilars: Upcoming Patent Expirations and Market Entry
Biosimilars are set to transform healthcare as major biologics like Keytruda and Eylea lose patent protection between 2025 and 2030. With savings up to 35%, these drugs offer the same effectiveness at a fraction of the cost - changing how patients, providers, and payers access life-saving treatments.
18 Jan 2026